Abigail L. Sedlacek

An immunocompetent, multifluorescent resource for real-time analysis of osteosarcoma progression, metastasis, and response to therapy

Despite substantial treatment improvements, the 5-year survival rate for metastatic osteosarcoma (OS) is still as low as 20%. Immunocompetent genetic mouse models of OS have been introduced, enabling in vivo OS studies. Here, we present the ROCCIA mouse, a quintuple-mutant extens...